Europe’s pharma industry saw a drop of 18.5% in deal activity during May 2019, when compared with the last 12-month average, according to GlobalData’s deals database.
Go deeper with GlobalData
- Embed this chart
Embed this chart into your website
Copy and paste the code below into your website to display the chart.
A total of 22 pharma industry deals worth $1.21bn were announced for the region in May 2019, against the 12-month average of 27 deals.
Of all the deal types, M&A saw most activity in May 2019 with ten transactions, representing a 45.5% share for the region.
In second place was venture financing with ten deals, followed by private equity deals with two transactions, respectively capturing a 45.5% and 9.1% share of the overall deal activity for the month.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataIn terms of value of deals, M&A was the leading category in Europe’s pharma industry with $1.09bn, followed by venture financing with $116.48m.
Europe pharma industry deals in May 2019: Top deals
The top five pharma deals accounted for 95.7% of the overall value during May 2019.
The combined value of the top five pharma deals stood at $1.16bn, against the overall value of $1.21bn recorded for the month. The top announced pharma deal tracked by GlobalData in May 2019 was Pfizer’s $810m acquisition of Therachon.
In second place was the $167m acquisition of Nuevolution by Amgen and in third place was Thermo Fisher Scientific‘s $100.83m asset transaction with GlaxoSmithKline.
The $44.44m venture financing of Promethera Biosciences by Ci:z Investment, Itochu, Korea Investment Partners, MediPal, Mirae Asset Capital, Mitsui &Global Investment Inc, My Family Office and Shinsei Capital Partners; BioGeneration Ventures, Capricorn Health-Tech Fund, Fund+, Michigan Investment in New Technology Startups, Participatie Maatschappij Vlaanderen, Perceptive Advisors, Qbic Venture Partners, V-Bio Ventures, Flanders Institute for Biotechnology and Wellington Partners Venture Capital’s venture financing of Confo Therapeutics for $33.58m held fourth and fifth positions, respectively.
Verdict deals analysis methodology
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.
